AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Reviva Pharmaceuticals Holdings Inc.

Healthcare US RVPH

4.31USD
0.06(1.41%)

Last update at 2024-02-22T20:57:00Z

Day Range

4.194.33
LowHigh

52 Week Range

3.179.25
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.31852M -8.51587M -3.78259M -0.84603M -
Minority interest - - - - -
Net income -24.33929M -8.52188M -3.78339M -0.84683M -
Selling general administrative 5.36M 5.25M 2.14M 0.18M -
Selling and marketing expenses - - - - -
Gross profit - - -0.72474M - -
Reconciled depreciation - 0.00000M 0.00059M 0.00064M -
Ebit -24.30661M -10.10451M -2.43465M -0.37686M -1.12188M
Ebitda -24.11190M -10.10451M -2.32888M -0.37601M -
Depreciation and amortization 0.19M 1.59M 0.11M 0.00085M -
Non operating income net other - - - - -
Operating income -24.30661M -10.10451M -2.43465M -0.37686M -
Other operating expenses 24.31M 10.10M 2.43M 0.38M -
Interest expense 0.18M 0.00241M 1.45M 0.47M 0.00000M
Tax provision 0.02M 0.00600M 0.00080M 0.00080M -
Interest income 0.18M - 0.11M 0.00020M -
Net interest income 0.18M -0.00241M -1.34794M -0.46917M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.00600M 0.00080M 0.00080M 0.00080M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 24.31M 10.10M 2.43M 0.38M -
Cost of revenue - - 0.72M - -
Total other income expense net -0.01191M 1.59M -1.34794M -0.46917M -
Discontinued operations - - - - -
Net income from continuing ops -24.33929M -8.52188M -3.78339M -0.84683M -
Net income applicable to common shares -24.33929M -8.52188M -3.78339M -0.84683M -1.68036M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 18.92M 31.40M 8.76M 0.00260M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.40M 1.72M 0.07M - -
Total liab 6.61M 2.72M 1.33M 6.81M -
Total stockholder equity 12.32M 28.69M 7.43M -6.81143M -
Deferred long term liab - - - - -
Other current liab 2.52M 1.84M 0.32M 0.10M 0.11M
Common stock 0.00204M 0.00144M 0.00092M 0.00062M 0.00062M
Capital stock 0.00204M 0.00144M 0.00092M 29.07M -
Retained earnings -91.17126M -66.83197M -58.31009M -54.52670M -53.67987M
Other liab 0.57M 0.37M 1.96M - -
Good will - - - - -
Other assets 0.40M 1.72M 0.00182M 0.00182M 0.00182M
Cash 18.52M 29.69M 8.76M 0.00019M -
Cash and equivalents - - - - -
Total current liabilities 6.04M 2.34M 1.33M 6.81M 6.09M
Current deferred revenue - - - 2.72M -
Net debt -18.51986M -29.68794M -8.76046M 3.76M -
Short term debt - - - 3.77M -
Short long term debt - - - 3.77M -
Short long term debt total - - - 3.77M -
Other stockholder equity 103.49M 95.52M 65.74M 73.17M -
Property plant equipment - - - 0.00059M 0.00124M
Total current assets 18.92M 31.40M 8.76M 0.00019M 0.12M
Long term investments - - - - -
Net tangible assets 12.32M 28.69M 7.43M -35.88140M -35.03457M
Short term investments - - - 65.24M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.52M 0.51M 1.01M 0.22M 0.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -54.52670M -
Additional paid in capital - - - - -
Common stock total equity - - 0.00092M 0.00062M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.00182M 0.00182M -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00182M 0.00241M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - -
Change to liabilities 3.01M -0.49846M 0.78M 0.16M -0.00665M
Total cashflows from investing activities - - - - -
Net borrowings - - 3.11M 0.10M 0.17M
Total cash from financing activities 7.79M 31.60M 12.49M 0.10M 0.17M
Change to operating activities 2.00M -0.20371M -3.10466M 0.48M 0.54M
Net income -24.33929M -8.52188M -3.78339M -0.84683M -1.68036M
Change in cash -11.16809M 20.93M 8.76M -0.11844M -0.89636M
Begin period cash flow 29.69M 8.76M 0.00019M 0.12M -
End period cash flow 18.52M 29.69M 8.76M 0.00019M 0.12M
Total cash from operating activities -18.96058M -10.66846M -3.72569M -0.21844M -1.07136M
Issuance of capital stock 7.77M 31.50M - - -
Depreciation - 0.00000M 0.00059M 0.00064M 0.00102M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.02M 0.10M 12.49M 0.10M 9.38M
Change to netincome 0.37M -1.44441M 2.39M -0.00641M 0.06M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5.01M -0.70217M -2.32956M 0.63M -
Stock based compensation 0.18M 0.11M - 0.00000M -
Other non cash items 0.19M -1.55113M 2.39M -0.00641M -
Free cash flow -18.96058M -10.66846M -3.72569M -0.21844M -

Fundamentals

  • Previous Close 4.25
  • Market Cap143.64M
  • Volume94933
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-10.10392M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM0.0
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.68

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RVPH
Reviva Pharmaceuticals Holdings Inc.
0.06 1.41% 4.31 0.0 0.0 0.0 69.86 0.0 -2.6215
NVO
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

Reviva Pharmaceuticals Holdings Inc.

19925 Stevens Creek Boulevard, Cupertino, CA, United States, 95014

Key Executives

Name Title Year Born
Dr. Laxminarayan Bhat Ph.D. Founder, CEO, Pres & Director 1965
Mr. Narayan Prabhu Chief Financial Officer 1972

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).